POSEIDON groups and their distinct reproductive outcomes: Effectiveness and cost-effectiveness insights from real-world data research

Esteves S. C., YARALI H., Vuong L. N., Conforti A., Humaidan P., Alviggi C.

Best Practice and Research: Clinical Obstetrics and Gynaecology, cilt.85, ss.159-187, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 85
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.bpobgyn.2022.05.003
  • Dergi Adı: Best Practice and Research: Clinical Obstetrics and Gynaecology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.159-187
  • Anahtar Kelimeler: Assisted reproductive technology, Infertility, ART calculator, Cumulative delivery rate, POSEIDON criteria, Real-word data
  • Hacettepe Üniversitesi Adresli: Evet

Özet

© 2022The Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) criteria identify and classify the so-called ‘low-prognosis’ patients undergoing assisted reproductive technology (ART). Recent large-scale studies using real-world data (RWD) have shown that patients classified under this system have distinct reproductive outcomes. Moreover, these studies also confirm that POSEIDON patients are commonly found in fertility centers. RWD has substantiated the validity of the POSEIDON biomarkers' thresholds (antral follicle count [AFC] and/or anti-Müllerian hormone [AMH]) for patient classification. Lastly, a predictive model has been developed and validated to estimate the POSEIDON metric of success (i.e., number of oocytes needed to achieve at least one euploid blastocyst). Although more evidence is needed in this area, current insights from RWD research indicate that infertility patients can be counseled and managed more effectively under the POSEIDON scope, with potential gains for all parties involved.